Juliana M.L. Biondo

Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen

Meghan C. Thompson, Rosemary Harrup, Catherine C. Coombs et al. · Blood Advances · 2022 · 57 citations · Full text

Medicine, Hematology, Oncology +13

MAJIC: A Phase III Trial of Acalabrutinib + Venetoclax versus Venetoclax + Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Christine E. Ryan, Matthew S. Davids, Richard Hermann et al. · Future Oncology · 2022 · 35 citations · Full text

Medicine, Hematology, Oncology +17

LONG‐TERM FOLLOW‐UP OF MULTICENTER PHASE II TRIAL OF ZANUBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX (BOVEN) IN PREVIOUSLY UNTREATED PATIENTS WITH CLL/SLL

Jacob D. Soumerai, Ahmet Doǧan, Venkatraman Seshan et al. · Hematological Oncology · 2023 · 17 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: <i>post-hoc</i> analyses from the phase III MURANO study

Anthony R. Mato, Jeff P. Sharman, Juliana M.L. Biondo et al. · Haematologica · 2020 · 16 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

Outcomes of Ibrutinib (Ibr) Therapy in Ibr-Naïve Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Progressing after Venetoclax (Ven)

Jennifer R. Brown, Matthew S. Davids, Julie Chang et al. · Blood · 2019 · 13 citations

Medicine, Hematology, Oncology +14